MCRB · Seres Therapeutics, Inc. · Webcasts, Transcripts & Audio
$1.40
-0.01 (-0.71%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2025 earnings call transcript
Going-concern doubt
— flagged Nov 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Therefore, there is substantial doubt about our ability to continue as a going concern for at least 12 months from the date that our condensed consolidated financial statements for the nine months ended September 30, 2026 were issued.”View the 10-Q filed Nov 4, 2026
Market Cap
$14.27M
Shares
10.20M
Volume · Nov 13
59.95K
Avg daily vol (3M)
73.12K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Seres Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Seres Therapeutics, Inc. (MCRB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY25 · Q3
2025-11-05
Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript
Positive tone
Investigator-sponsored IREC study at MSK
Capital needs and funding dependency
CARB-X non-dilutive funding and oral liquid formulation
Revenue
$351,000
Diluted EPS
$0.94
▼ 91.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript
Positive tone
CER155 Phase II development and design
FDA engagement and regulatory progress
Capital and business development needs
Revenue
$0
Diluted EPS
$-2.27
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript
Positive tone
SER-155 Phase 2 Study Design and Timeline
FDA Interaction and Regulatory Path
Clinical Data and Translational Evidence
Revenue
$0
Diluted EPS
$3.75
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript
Positive tone
SER-155 clinical progress and BSI risk reduction
FDA engagement and breakthrough therapy designation
Exploratory biomarker data and mechanism of action
Revenue
$0*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript
Confident tone
SER-155 clinical results and pipeline
VOWST sale to Nestlé Health Science
Partnership strategy for SER-155
Revenue
$0
▼ 100% YoY Diluted EPS
$11.63
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript
Positive tone
SER-155 Phase Ib Cohort 2 readout
SER-147 program in metabolic disease
Corporate restructuring and pipeline focus
Revenue
$0
▼ 100% YoY Diluted EPS
$-4.34
▼ 160.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript
Balanced tone
VOWST Commercial Launch
Nestle Partnership & Launch Refinements
SER-155 Clinical Program
Revenue
$0
Diluted EPS
$-5.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-05
Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript
Positive tone
VOWST launch and commercial performance
SER-155 clinical readout and pipeline
Hospital outflow and HCP adoption
Revenue
−$126.26M*
▼ 13049.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript
Revenue
$310,000
▼ 91% YoY Diluted EPS
$-7.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Seres Therapeutics, Inc. (MCRB) Q2 2023 Earnings Call Transcript
Revenue
$126.47M
▲ 10300.7% YoY Diluted EPS
$7.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Seres Therapeutics, Inc. (MCRB) Q1 2023 Earnings Call Transcript
Revenue
−$522,000
▼ 135% YoY Diluted EPS
$-11.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript
Revenue
$975,000*
▼ 86.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Seres Therapeutics, Inc. (MCRB) Q3 2022 Earnings Call Transcript
Revenue
$3.44M
▼ 97.3% YoY Diluted EPS
$-9.80
▼ 168.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Seres Therapeutics, Inc. (MCRB) Q2 2022 Earnings Call Transcript
Revenue
$1.22M
▼ 76.9% YoY Diluted EPS
$-14.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Seres Therapeutics, Inc. (MCRB) Q1 2022 Earnings Call Transcript
Revenue
$1.49M
▼ 73.9% YoY Diluted EPS
$-12.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Seres Therapeutics, Inc. (MCRB) Q4 2021 Earnings Call Transcript
Revenue
$7.22M*
▼ 58.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Seres Therapeutics, Inc. (MCRB) Q3 2021 Earnings Call Transcript
Revenue
$126.72M
▲ 8843.2% YoY Diluted EPS
$14.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Seres Therapeutics, Inc. (MCRB) Q2 2021 Earnings Call Transcript
Revenue
$5.26M
▼ 12.9% YoY Diluted EPS
$-10.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Seres Therapeutics, Inc. (MCRB) Q1 2021 Earnings Call Transcript
Revenue
$5.72M
▼ 30.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-02
Seres Therapeutics, Inc. (MCRB) Q4 2020 Earnings Call Transcript
Revenue
$17.56M*
▲ 130.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Date not confirmed
Seres Therapeutics, Inc. (MCRB) Q3 2020 Earnings Call Transcript
Revenue
$1.42M
▼ 79.8% YoY Diluted EPS
$-7.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Seres Therapeutics, Inc. (MCRB) Q1 2020 Earnings Call Transcript
Revenue
$8.19M
▲ 11.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-02
Seres Therapeutics, Inc. (MCRB) Q4 2019 Earnings Call
Revenue
$7.62M*
▼ 28.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–23 of 23 webcasts
Key facts
CIK
1609809
CUSIP
81750R201
13F (30d)
42 filings
29 filers
Visit website
Investor relations